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Patients with severe psychotic disorders such as schizophrenia, schizoaffective,
and bipolar disorders frequently suffer from concomitant substance use disorders
(SUDs)–Dual Disorder (DD) patients. In order to better understand current practices
for management of patients with psychotic episodes and concomitant SUD in Italy,
we carried out a survey of psychiatrists on current routine practice among prescribers.
These aspects can help to identify at-risk patients, improve current prescribing practices,
and favor early intervention. An ad hoc survey of 17 questions was administered to
psychiatrists via electronic polling and on-line distribution; 448 completed questionnaires
were collected. Comorbid substance abuse was most frequently diagnosed within
the context of anxiety disorder (46%), followed by bipolar disorder (25%), and
schizophrenia/schizoaffective disorder (12%). The vast majority of respondents felt that
patient management was becoming more complex due to substance abuse. The areas
reported to be most affected in patients with SUD were functioning, interpersonal
relations, and impulsivity, while sensory perception disorders, ideation, agitation, and
impulsivity were the most frequently reported symptoms. In the acute setting, haloperidol
was used as the first-line agent of choice followed by aripiprazole and olanzapine. In the
maintenance phase, aripiprazole was the dominantly used first-line agent, followed by
olanzapine. Almost half of respondents used long-acting agents, while about one-third
did not. Among those prescribing long-acting agents, efficacy, control of impulsivity,
and control of specific symptoms were cited as motivators, while in the maintenance
phase, better adherence, and tolerability were mainly cited. From the responses to the
present survey, it is clear that the respondents are aware of the problem of SUD in
psychotic patients. While treatment be optimized in terms of the choice and formulation
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of antipsychotics, greater emphasis should be placed on efficacy, tolerability, and the
negative metabolic consequences of some antipsychotics. When considering the ideal
antipsychotic, long-acting agents were considered to be superior in reducing relapse,
even if current treatment guidelines often give preference to oral formulations.
Keywords: schizophrenia, psychosis, psychotic disorder, substance use disorder, survey, management, dual
disorder
INTRODUCTION
Patients affected by severe psychiatric disorders such as
schizophrenia, schizoaffective, and bipolar disorders, with
psychotic features, frequently suffer from concomitant substance
use disorders (SUDs)–Dual Disorder (DD; nicotine excluded)
patients. These are defined as conditions in which abuse of
or dependence on substances such as alcohol, cocaine, opioids,
phencyclidine, amphetamine, cannabis, or nicotine, negatively
impacts on family and social life, work, and school. SUDs are also
associated with impairment or distress (even if formal criteria of
dependence are not necessarily met), and may causes financial
problems (1).
WHO Mental Health surveys have suggested an association
between psychotic experiences and SUDs, even if not all types
of SUDs are associated with psychotic episodes (2). About 25–
50% of psychotic patients are diagnosed with schizophrenia and a
concomitant addiction disorder (3). Moreover, the prevalence of
SUD is 25.1% in patients with schizophrenia and 20.1% in those
with bipolar disorder, with young men affected by schizophrenia
having the highest prevalence of non-alcohol drug-use disorder
(4). Co-occurrent drug use is a frequent condition among
patients presenting with a first episode of psychosis, with a
prevalence ranging from 25 to 60% (5). In addition, substance
abuse might trigger psychotic symptoms in certain individuals,
since substances may be used to self-medicate psychotic
symptoms (6, 7). Importantly, DD/psychosis is associated with
more frequent psychotic relapses and emergency admissions,
and with a tendency for chronicity (8); self-medication may also
be related to the presence of psychotic symptoms (9). In this
complex setting, adequate treatment is difficult to provide, which
is further hampered by the known poor compliance of patients.
Psychotic patients with co-occurrent drug abuse may be
more sensitive to the side effects of antipsychotics (i.e.,
extrapyramidal, cardiovascular, and metabolic) and therefore
choosing agents proven with a low liability for such adverse
events is warranted (10). Moreover, long acting antipsychotics
with the above characteristics may be preferred in this clinical
setting both reasons related to adherence and pharmacokinetic
considerations (11).
There has been little effort to deliver a common clinical and
procedural framework for DD patients and separate policies have
focused on either severe mental health problems or addiction
(12). At present, the aim of SUD treatment and prevention
strategies has changed from a reduction in the use of substances
to a greater prevention of the social and clinical consequences
of substance use (12). While in some countries mental health
services lead treatment programs, in others, such as Italy,
addiction services normally care for people with SUD, including
those with psychotic episodes. In Italy, indeed, the Drug
Addiction Units [Servizi per le tossicodipendenze (SERT); and
servizi per le dipendenze (SERD)] have generally been considered
autonomous, and separate fromCommunity Psychiatric Services,
despite the frequent co-presence of a psychotic disorder and
SUD. This has been increasingly recognized as ineffective, and
the Departments of Mental Health (DSM) now allow access
to users who were heretofore not treated at such centers.
In addition, many traditional Therapeutic Communities are
also recognizing the difficulty of working with patients with a
psychotic disorder and SUD and have begun to adopt the services
offered accordingly. In fact, DSM and SERD are increasingly
called upon to adopt convergent guidelines and intervention
procedures, for an integrated, multi-dimensional, and targeted
interventions. This is especially relevant when managing chronic
pathologies that require long-term treatment and the use of
multiple resources.
In order to shed more light on the current practices
for the management of patients with psychotic episodes
and concomitant SUD in Italy, we have carried out a
survey of psychiatrists on current routine practice among
prescribers. Particular emphasis was put on clinical practice in
patients suffering from schizophrenia/schizoaffective disorder
and substance use (DD/psychosis). Beyond the Italian mental
health and Addiction Service system, these aspects could be
relevant to identify at-risk patients, improve current prescribing
practices, and possibly implement early intervention programs.
MATERIALS AND METHODS
General Description of Survey
This was an ad hoc survey consisting of 17 questions intended to
investigate the models of care of psychotic patients with
concomitant SUD in Italy regarding the prescribing practices
of antipsychotic medications in psychotic patients with SUD.
The survey was drafted by the authors of this article and
made available for completion to psychiatrists throughout the
country under the aegis of the Società Italiana Psichiatria
delle Dipendenze1 The completed surveys were collected in
two ways. First, through an electronic poll carried out at
the national congress of Società Italiana di Psicopatologia
(SOPSI) in 2017, where 98/350 participants responded to the
questionnaire (28%). This percentage can be considered to be
an adequate representation of participants based on literature
data (12–15). In a second ad hoc, snowball sampling recruitment
1http://www.sipdip.it/documenti/Report%20finale%20PADDI%20Study.pdf
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technique (in which participants were asked to recruit additional
subjects from acquaintances), 5,155 psychiatrist subscribers to
the Medikey newsletter (https://ssl.medikey.it/) were asked to
fill in the questionnaire, of whom 350 (6.8%) did. Thus, a total
of 448 completed questionnaires were collected. Participation
in compilation of the questionnaires was entirely voluntary,
and no incentive for participation was offered. A link was
provided to an online participant information sheet, and
upon consenting were participants redirected to the online
questionnaire. There were no mandatory responses in the
questionnaire and participants were free to withdraw at any
stage in compilation, and participants wishing to withdraw could
simply close the relevant page. All answers and questionnaires
were completely anonymous, and other than the information
detailed below no personal identifying information was collected.
The survey included a series of questions on the respondents’
demographics (age, sex, specialty, position, type of setting,
and geographic location), besides the 17 questions. Of
these, questions 1–6 investigated the models of care of
psychotic patients with concomitant SUD, questions 7–10
queried about the characteristics of patients seen in daily
practice by psychiatrists, and questions 11–17 focused on the
prescription practices and long-term formulations employed
in the subgroup of patients with schizophrenia/schizoaffective
disorder. The translated questionnaire is shown in Data Sheet 1
in Supplementary Material.
RESULTS
Demographics of Respondents
A total of 448 questionnaires were collected. As summarized
in Table 1, 56.5% of the respondents were men and nearly
62% were older than 50 years; >40% responded that they were
Head of Department or similar, while only 7.6% were resident
fellows.
The type of settings of respondents was fairly well-
balanced: indeed, over 40% worked in specialized centers, while
the remainder was divided between local structures, private
practice and addiction services, besides residential settings.
The respondents were from all areas of Italy, although the
highest percentages were from Lombardy (16.3%), Lazio (10.9%),
Campania (9.4%), and Sicily (9.2%).
Models of Care of Psychiatric Patients
With Concomitant SUD (Q1-Q6)
In the Italian practice, comorbid substance abuse was
most frequently diagnosed within the context of anxiety
disorder (46%), followed by bipolar disorder (25%), and
schizophrenia/schizoaffective disorder (12%) (Q1, Table 2).
Notably, 84.4% of respondents felt that patient management
was becoming more complex due to substance abuse, while
the reminder said “no” or “don’t know” (Q2). With regard to
the most prevalent type of structure for psychiatric patients
with comorbid substance abuse in their center (Q3), 49%
responded that co-management with addiction services was the
optimal approach, followed by management by a psychiatrist
within the context of a multidisciplinary group (21%). Only
TABLE 1 | Demographics of study respondents.
Percentage
Sex
Male 56.5
Female 43.5
Age (years)
<40 19.4
41–50 18.8
51–60 38.0
>60 23.9
Specialty
Psychiatry 88.8
Neurology 4.7
Other 6.5
Position
Director of integrated department/center 11.0
Head of simplified structure 20.5
High-level specialist 19.2
Hospital physician* 41.7
Resident fellow 7.6
Type of structure
Hospital structure 20.5
Day hospital services 42.6
Residential setting 7.6
Addiction services 14.7
Private practice 14.5
*Not general practitioners.
12% felt that exclusive psychiatric management was the best
approach. The clinical choice was overwhelmingly acknowledged
as the major driver (48%) in the decision of the model of
care, followed by the good working relationship between
client services (18%); only 4% said that costs were a major
motivator in their choice (Q4). The overall level of integration
with other services (Q5) was mostly viewed as good/excellent
(16.7%) or acceptable (39.3%). However, 31.9% deemed it as
unacceptable. When asked in what context psychiatric patients
with comorbid substance abuse are presented (Q6), a wide variety
of responses was given: addiction services (27%), specialized
center (26%), regional/local services (19%), and emergency
services (15%).
Characteristics of Patients With Psychotic
Episodes and SUD (Q7–Q10)
The areas reported to be the most affected in patients with
comorbid substance abuse (Figure 1, Q7) were functioning,
interpersonal relations, and impulsivity, while more
heterogeneous responses were given for the remaining areas.
Questions 8 and 9 were optional and are not presented herein as
only a small number of responses were collected. With regard to
the types of substances used in psychiatric patients, a wide variety
of responses were seen (Figure 2, Q10). Cannabis and alcohol
were among those most used, although stimulants were also used
in more than 40% of patients. Fewer but significant proportions
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TABLE 2 | Questions regarding comorbid substance abuse and various treatment centers.
Question Answers % Responders* (%)
1. Which of the following conditions are most frequently diagnosed as
comorbid at your center?
Schizophrenia/schizoaffective disorder and SUD 12
Bipolar disorder and SUD 25
Mood disorders (other) and SUD 7
Anxiety disorder and SUD 3
Personality disorders and SUD 46
2. Do you have the impression that your work has become more complex in
the last 5 years due to comorbidities?
Yes 84
No 8
3. What is the prevalent model used for management of patients in your
structure?
Management by a psychiatrist alone 12
Management by a psychiatrist within a multidisciplinary group 21
Co-management with addiction services 49
Referred to addiction services 4
Insertion in a residential structure 3
4. What is the reason for adopting the model chosen? Clinical choice 48
Good working relationship between services 18
Poor working relationship between services 14
Cost considerations 4
Insertion in a residential structure 5
5. What is the level of integration with other services? Poor 32
Acceptable 39
Good 15
Excellent 2
6. What service do you preferentially use as initial treatment for comorbid
SUD?
Emergency room 15
Hospital structure 19
Day hospital services 26
Addiction services 27
Community therapy 0
*The number of non-responders is not indicated.
SUD, substance use disorder.
of patients were using opioids or other drugs, and even fewer
new synthetic drugs or plant-derived hallucinogens. Of note,
about 60% of patients had used more than one substance.
Patients With
Schizophrenia/Schizoaffective Disorder
and SUD: Prescribing Practices and
Long-Term Agents (Q11–Q17)
In patients with schizophrenia/schizoaffective disorder and
comorbid substance abuse, the symptoms most frequently
reported (Figure 3, Q11) were sensory perception disorders,
ideation, agitation, and impulsivity. Of note, negative symptoms
were predominant in a small proportion of subjects. In their
daily practice, 51.9% of respondents used to treat differently this
subgroup from other psychiatric patients, whereas 23.2% did not
(25.0% did not respond) (Q12).
In the acute setting (Figure 4A), haloperidol was widely
seen as the first-line agent of choice followed by aripiprazole
and olanzapine. Paliperidone was the most commonly chosen
second-line agent. In the maintenance phase, aripiprazole was
the prevalent choice as first-line agent, followed by olanzapine
(Figure 4B). Quetiapine and risperidone were also frequently
used.
The remaining questions queried about the use of long-acting
agents 48.6% of respondents used long acting agents, while 35.0%
did not (Q14). 74.9% prescribed prevalently an atypical agent,
while 10.5, 8.2, and 6.4 stated that they usually preferred neither
atypical or typical agents, a long-acting acting combined with an
oral agent, and a typical agent, respectively. Figure 5 shows the
agents rated as first, second, or third choice. Paliperidone was the
long-acting agent most widely adopted in all three lines, followed
by aripiprazole, haloperidol, and risperidone.
When asked about the reason for choosing a long-acting
antipsychotic in the acute and maintenance phases (Q15),
there was a wide range of responses for the former, most
frequently citing efficacy, control of impulsivity, and control of
specific symptoms (Figure 6). In the maintenance phase, better
adherence and tolerability were the main drivers. Regarding the
most suitable patient for a long-acting antipsychotic in those with
and without comorbid substance use (Figure 7, Q16), a large
proportion of participants did not respond, while many indicated
the subjects with poor compliance and poorly controlled by
oral therapies. In addition, respondents often cited those living
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FIGURE 1 | What areas are most compromised in psychotic patients with comorbid substance abuse? Value expressed on a scale of 1–5 where 1, not important; 2,
not very important; 3, somewhat important; 4, important; 5, very important.
FIGURE 2 | What type of substances are most frequently used by patients with psychotic episodes? Value expressed on a scale of 1–5 where 1, not used; 2,
infrequent; 3, somewhat used; 4, often used; 5, very often used *cocaine, amphetamines; ** e.g., mephedrone, synthetic cannabinoids, Spice drugs, latest generation
ecstasy derivatives, ketamine, and derivatives; ***hallucinogenic mushrooms, Salvia divinorum, Ayahuasca, Mitragyna speciosa-kratom.
alone or who were not well-supported by a caregiver as good
candidates.
Finally, according to 43% of respondents the concomitant
use of other psychoactive drugs in those being treated with
long-acting antipsychotics is frequent, whereas another 43%
responded no (Q17). Interestingly, there was little consensus on
what types of drugs were more commonly used in concomitance
(Figure 8).
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FIGURE 3 | What symptoms are most represented in patients with schizophrenia/schizoaffective disorder and SUD? Value expressed on a scale of 1–5 where 1, rare;
2, infrequent; 3, somewhat frequent; 4, often; 5, very often.
DISCUSSION
The respondents of the present survey were primarily
psychiatrists working in a wide range of clinical settings
significantly representing real-life practice. Addiction services do
not commonly treat psychotic patients with SUD, representing
only 14.7% of respondents. Indeed, from the present survey,
the majority of the psychotic patients with SUD are treated at
outpatient services and in hospital (63.1% combined) in line with
what is believed to be the optimal approach, and much fewer in
residential settings. In addition, general psychiatrists are likely to
be those who formulate a diagnosis of SUD and psychosis, and
prescribers may not always have adequate training on diagnosis
of a DD.
It was our intention to gain more information about the
current prescribing practices for patients with schizophrenia and
SUD in Italy. The results of the present survey are consistent with
previous studies indicating that SUD is common in patients with
schizophrenia. Interestingly, the vast majority of respondents felt
that management of comorbid SUD is becoming more complex.
Thus, on one hand it is not surprising that many viewed the
use of a multidisciplinary team as the optimal approach for such
patients. It is also reassuring that costs did not appear to be
a major motivator for this choice. As expected, interpersonal
relationships and overall functioning were among the areas most
seen to be affected by comorbid substance abuse, with patients
abusing a variety of substances, most often alcohol and cannabis,
but also other drugs. The majority of patients also had poly-
substance abuse. The present survey can be seen as an extension
of a previous one carried out over a decade ago on DDs in Italy
(16).
It is noteworthy that negative symptoms were seen as
predominant in only a minority of patients, with other symptoms
being more prevalent, such as sensory perception disorders,
ideation, agitation, and impulsivity. This could perhaps suggest
that the antipsychotic treatment was not optimal in terms of
the agent prescribed and/or dosing. However, such additional
factors were not queried in the present survey. Nonetheless, in
the acute phase haloperidol was often the agent of first choice,
followed by the second-line agents aripiprazole and paliperidone.
In the maintenance phase, aripiprazole appeared to be the first-
line choice, followed by other second-line agents. This finding
confirms that second-line agents are indeed widely prescribed
in schizophrenic patients with comorbid substance abuse, and
that those with lower metabolic impact are also favored. The
prescribing preferences referred would also seem to indicate that
the choice of agent is not specifically related to the presence of
a single diagnosis of psychosis or DD/psychosis. Since reward
deficiency syndrome is more easily established in patients with
SUD, this suggests that the dopaminergic resources of those
with SUD are already destabilized by substance use (16), with
the development of anhedonia and/or hypophoria as probably
the most relevant clinical symptoms (17). It is now commonly
agreed that dopamine is a major neurotransmitter in terms of
reward dependence, even if there is some controversy regarding
its clinical modulation in treatment and prevention of prevent
relapse for SUD. While many have advocated that medications
blocking dopamine should be favored, it can also be argued that
short-term blockade of D2 receptors is warranted, but that long-
term treatment should activate and not completely inhibit D2
receptors in order to enhance the functional connectivity of brain
reward circuits (16, 18–23).
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FIGURE 4 | Which agents do you most often prescribe as first-, second-, or third-line in patients with schizophrenia/schizoaffective disorder and SUD in the acute (A)
and in maintenance (B) setting?
Some psychoactive substances and medications can be
related to “Reward Deficiency Syndrome,” which was originally
described as an outcome of chronic alcohol and stimulant
abuse, and a highly relevant topic of which clinicians should
be aware within the context of SUD. In part, it links with the
a-motivational syndrome (AS) (24), displayed as an expression
of chronic cannabis intoxication, but which is closely related to
post-withdrawal syndrome (PWS) described byMartin et al. as an
enduring pathologic state in abstinent detoxified opiate addicts
(25). From a withdrawal-related point of view, through each
detoxification cycle the patient passes from the acute withdrawal
state (counter-polar to intoxication—psychomotor retardation
in case of cocaine acute withdrawal) to a later and enduring
drug-free state featuring symptoms of anhedonia or hypophoria,
looming as acquired discomfort related to the absence of drug-
related stimulation. Hypophoria includes somatic, vegetative
(sleep), mood, and anxiety symptoms such as susceptible or
irritable (depressed) mood, amplified pain perception, inability
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FIGURE 5 | Which long-acting agent do you prefer to prescribe as first, second, and third line therapy?
FIGURE 6 | What is the main motivating factor for choice of a long-acting antipsychotic?
to perform simple tasks, and make normal efforts, and inability
to experience reward in any way other than substance use.
This syndrome closely resembles the subthreshold symptoms
of dysthymia and the residual symptoms of chronic bipolar
disorder (26, 27). This is one of the possible ways of relapsing
behavior.
With regards to the use of long-acting antipsychotics, roughly
one-half responded that they use these agents in clinical practice,
with clear preference for the use of an atypical agent in this
formulation, in line with a recent study recently conducted in
Italy (28). In this regard, a study comparing long-acting injectable
formulations of aripiprazole and paliperidone in patients with
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FIGURE 7 | In which type of patient with SUD are long-acting antipsychotics most suited?
FIGURE 8 | Which types of drugs are most widely used in combination with a long-acting antipsychotic? Value expressed on a scale of 1–4 to estimate the frequency,
1 for most frequent use and 4 for less frequent use.
comorbid psychosis and SUD found that both agents improved
clinical status and QoL and reduced substance craving at 1
year (29). Among long-acting formulations, paliperidone was
widely favored in the present survey. Respondents cited efficacy
and better adherence as major motivators for prescription of
a long-acting agent in the maintenance phase, along with
good tolerability. Patients with poor compliance and those
living alone with inadequate caregiver support were believed
to be most suited for a long-acting antipsychotic. Lastly, there
was little agreement as to which type of drugs were most
commonly used in combination with a long-acting antipsychotic.
This could be indicative that many different types of drugs
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are used in conjunction with long-acting agents, including
oral antipsychotics, mood stabilizers, benzodiazepines, and
antidepressants.
It is difficult to compare the present results with those in
the literature as there is limited real-life data on prescribing
habits in patients with schizophrenia and comorbid SUD. In
a recent survey among French psychiatrists, most psychiatrists
used second-generation antipsychotics, and preferentially an
oral formulation, in the treatment of schizophrenia (30).
Long-acting agents were prescribed in about one-third of
schizophrenic patients, and the duration and type of practice
did not influence the class or formulation of antipsychotics
used. As perhaps can be inferred from the present survey,
in that survey personal experience, government regulatory
approval, and guidelines for the treatment of schizophrenia
were the main factors that guided decision-making. However,
that survey was not specific on patients with comorbid
substance abuse. In a survey of practice in 7 Central and
Eastern European Countries, oral atypical antipsychotics, mostly
risperidone, olanzapine, clozapine, were among those most
commonly prescribed for schizophrenia (31). As in the present
survey, anxiolytics (70%), antidepressants (42%), and mood-
stabilizers (27%) were commonly co-prescribed in the survey
mentioned.
In previous survey of Italian psychiatrists treating
schizophrenia, while efficacy and tolerability were among
the most widely used factors used to evaluate treatment
outcomes in patients with schizophrenia, overall quality
of life and global functioning were also considered to be
important. These findings were also mirrored in the present
survey. Notwithstanding, some discrepancies in quality of
care indicators have been revealed among Italian DSM, with
a percentage of inappropriate interventions ranging from 5.9
to 66.8% for pharmacological interventions, with significant
variability in monitoring of metabolic effects, psychosocial
rehabilitation, family involvement, and work (32). These results
underscore the greater need for monitoring of patients and
better integration of mental health services, aspects which were
also seen in the present survey as inadequate for a proportion of
respondents.
In this regard, it is worthwhile to stress that while
awareness is definitely increasing, psychiatrists should be vigilant
to the adverse metabolic effects of some second-generation
antipsychotics (33), especially the risk of reward deficiency
syndrome in substance user psychotic patients treated with
full blocking D2 antagonist. To improve the current situation,
additional efforts are still needed in order to improve training
programs as shown in a recent survey of 35 countries (34).
In considering the ideal antipsychotic, long-acting agents are
considered to be superior to their oral equivalents in reducing
relapse, even if current schizophrenia treatment guidelines often
give preference to oral formulations (35).
A relevant issue in long term therapy schizophrenia and
drug addiction comorbidity is represented by treatment-resistant
schizophrenia. Approximately 30% of schizophrenia patients do
not respond or respond poorly to antipsychotics treatment (36),
treatment resistant schizophrenia is defined as lack of response
to at least two different antipsychotics at 600mg chlorpromazine
equivalent and for the duration of treatment of at least 6 weeks.
These patients show reduction in milestone acquisition (37),
more cognitive impairment (38), and functioning deficits as well
as higher incidence of neurological soft signs (39) compared to
patients who respond to antipsychotic treatment.
The relationship between treatment resistance and drug
abuse is two-fold. Drug abuse or addiction, besides worsening
adherence to treatment, can interfere with the efficacy of
antipsychotics by worsening symptoms of the disease and/or
interacting with the pharmacodynamics of antipsychotics (40).
On the other hand, worsening of psychiatric symptoms
may be relevant to further induce abuse and/or addiction.
Long acting injectable antipsychotics could overcome some of
these issues by improving adherence and therefore excluding
false positive treatment-resistant patients, as well as possibly
increasing the availability of the antipsychotics at the receptor
level.
Overcoming these and other barriers in the future will
undoubtedly help to optimize management of the difficult-
to-treat group of patients with schizophrenia and comorbid
substance abuse. From the responses to the present survey, it
is clear that the respondents are aware of the problem of SUD
in psychotic patients. Not only can treatment be optimized
in terms of the choice and formulation of antipsychotics,
but greater emphasis should be placed on treatment efficacy,
tolerability, and especially the potentially negative metabolic
consequences of antipsychotics, with the consequent need for
better monitoring of patients. Despite the limitations of the
present study, such as possible bias related to the survey
techniques used and potential bias in the profile of responders,
it seems clear that new treatment paradigms will be needed,
and achieving these long-term goals will also require even
greater awareness and training. The present survey nonetheless
helps to better understand current routine practice among
prescribers.
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